Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – ...

Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...

AMSTERDAM, The Netherlands I June 20, 2025 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people ...

GRAND RAPIDS, MI, USA I June 20, 2025 I Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by ...

HONG KONG, China I June 20, 2025 I Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening ...

Company positioned to initiate multiple Phase 1 clinical trials in 2025 for ART-101 and additional novel radiopharmaceutical assets – ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo ...

SAN DIEGO, CA, USA I June 20, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial ...

BOSTON, MA, USA & CAMBRIDGE, UK I June 19, 2025 I Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction ...

In-vitro lab results confirmed that the Company’s cell targeting nanoparticles successfully entered cancer cells and avoided non-cancerous cells ...

COPENHAGEN, Denmark I June 18, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...